Your Health, We Care
Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.
FDA,2022.01
How does gilteritinib work?In patients with acute myeloid leukemia (AML), the bo···【more】
Release date：2026-04-14Recommended：42
What is Gilteritinib?Gilteritinib (generic name: gilteritinib) works in a fundam···【more】
Release date：2026-04-10Recommended：40
Indications and EfficacyThe main component of Gilteritinib Fumarate Tablets is g···【more】
Release date：2026-03-11Recommended：54
Gilteritinib is suitable for Leukemia.【more】
Release date：2026-01-06Recommended：30
